Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24361843 | 0.66 | KMT2A (0.30) | PDE10AKMT2A | |
| SCHEMBL14957158 | 0.65 | PDE3B (0.34) | SMN1; SMN2MAPTLMNAMEN1ALDH1A1 | |
| SCHEMBL5329219 | 0.64 | GPR84 (0.38) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5334619 | 0.64 | GPR84 (0.38) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5329525 | 0.64 | GPR84 (0.38) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL14147979 | 0.62 | GPR84 (0.38) | LMNA | |
| SCHEMBL12724876 | 0.62 | PIM1 (0.33) | SMN1; SMN2MAPTLMNAMEN1ALDH1A1 | |
| SCHEMBL4368060 | 0.61 | TLR8 (0.58) | TLR8SMN1; SMN2CASRLMNAUSP2 | |
| SCHEMBL12359188 | 0.61 | HTT (0.39) | TLR8SMN1; SMN2MAPTLMNAUSP2 | |
| SCHEMBL19226587 | 0.61 | NOS2 (0.35) | TLR8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208386-B2 | Inhibitors of protein arginine deiminases (PADs) and methods of preparation and use thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200339518-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES (PADS) AND METHODS OF PREPARATION AND USE THEREOF | UNIV MASSACHUSETTS (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208386-B2 | Inhibitors of protein arginine deiminases (PADs) and methods of preparation and use thereof | PADI2, PADI1, PADI4 | PDE10A 366/4885TLR8 4644/4885SMN1; SMN2 4551/4885 |
| US-20200339518-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES (PADS) AND METHODS OF PREPARATION AND USE THEREOF | PADI2, PADI1, PADI4 | PDE10A 366/4885TLR8 4644/4885SMN1; SMN2 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.